You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIloprost
Accession NumberDB01088  (APRD01027)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionIloprost is a synthetic analogue of prostacyclin PGI2. Iloprost dilates systemic and pulmonary arterial vascular beds. It is used to treat pulmonary arterial hypertension (PAH).
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
VentavisNebuliser solution10 μg/mlInhalation useBayer Schering Pharma Ag2003-09-16Not applicableEu
Ventavissolution.01 mg/mLrespiratory (inhalation)Actelion Pharmaceuticals US, Inc.2005-05-07Not applicableUs
VentavisNebuliser solution20 μg/mlInhalation useBayer Schering Pharma Ag2003-09-16Not applicableEu
VentavisNebuliser solution10 μg/mlInhalation useBayer Schering Pharma Ag2003-09-16Not applicableEu
VentavisNebuliser solution10 μg/mlInhalation useBayer Schering Pharma Ag2003-09-16Not applicableEu
Ventavissolution.02 mg/mLrespiratory (inhalation)Actelion Pharmaceuticals US, Inc.2009-08-24Not applicableUs
VentavisNebuliser solution10 μg/mlInhalation useBayer Schering Pharma Ag2003-09-16Not applicableEu
VentavisNebuliser solution10 μg/mlInhalation useBayer Schering Pharma Ag2003-09-16Not applicableEu
VentavisNebuliser solution10 μg/mlInhalation useBayer Schering Pharma Ag2003-09-16Not applicableEu
VentavisNebuliser solution10 μg/mlInhalation useBayer Schering Pharma Ag2003-09-16Not applicableEu
VentavisNebuliser solution20 μg/mlInhalation useBayer Schering Pharma Ag2003-09-16Not applicableEu
VentavisNebuliser solution10 μg/mlInhalation useBayer Schering Pharma Ag2003-09-16Not applicableEu
VentavisNebuliser solution20 μg/mlInhalation useBayer Schering Pharma Ag2003-09-16Not applicableEu
VentavisNebuliser solution10 μg/mlInhalation useBayer Schering Pharma Ag2003-09-16Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIJED5K35YGL
CAS number78919-13-8
WeightAverage: 360.494
Monoisotopic: 360.23005951
Chemical FormulaC22H32O4
InChI KeyHIFJCPQKFCZDDL-ACWOEMLNSA-N
InChI
InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1
IUPAC Name
5-[(2E,3aS,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-octahydropentalen-2-ylidene]pentanoic acid
SMILES
[H][C@]12C[C@@H](O)[[email protected]](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassFatty Acyls
Sub ClassEicosanoids
Direct ParentProstaglandins and related compounds
Alternative Parents
Substituents
  • Prostaglandin skeleton
  • Bicyclic monoterpenoid
  • Monoterpenoid
  • Fatty alcohol
  • Medium-chain hydroxy acid
  • Medium-chain fatty acid
  • Branched fatty acid
  • Hydroxy fatty acid
  • Cyclic alcohol
  • Secondary alcohol
  • Carboxylic acid
  • Carboxylic acid derivative
  • Monocarboxylic acid or derivatives
  • Organooxygen compound
  • Alcohol
  • Hydrocarbon derivative
  • Carbonyl group
  • Organic oxide
  • Organic oxygen compound
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationUsed for the treatment of pulmonary arterial hypertension.
PharmacodynamicsIloprost is a synthetic analogue of prostacyclin PGI2. Iloprost dilates systemic and pulmonary arterial vascular beds. It also affects platelet aggregation but the relevance of this effect to the treatment of pulmonary hypertension is unknown. The two diastereoisomers of iloprost differ in their potency in dilating blood vessels, with the 4S isomer substantially more potent than the 4R isomer.
Mechanism of actionIloprost is a second generation structural analog of prostacyclin (PGI) with about ten-fold greater potency than the first generation stable analogs, such as carbaprostacyclin. Iloprost binds with equal affinity to human prostacyclin (Prostanoid IP) and prostaglandin EP1 receptors. Iloprost constricts the ilium and fundus circular smooth muscle as strongly as prostaglandin E2 (PGE2) itself. Iloprost inhibits the ADP, thrombin, and collagen-induced aggregation of human platelets. In whole animals, iloprost acts as a vasodilator, hypotensive, antidiuretic, and prolongs bleeding time. All of these properties help to antagonize the pathological changes that take place in the small pulmonary arteries of patients with pulmonary hypertension.
Related Articles
AbsorptionRapidly absorbed with bioavailability of 63%
Volume of distribution
  • 0.7 to 0.8 L/kg
Protein binding60%
Metabolism

Primarily hepatic. Iloprost is metabolized principally via beta-oxidation of the carboxyl side chain.

Route of eliminationNot Available
Half life20-30 minutes
Clearance
  • 20 mL/min/kg [Normal subjects]
ToxicityOverdoses can lead to hypotension, headache, flushing, nausea, vomiting, and diarrhea.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9543
Blood Brain Barrier+0.5506
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.7459
P-glycoprotein inhibitor INon-inhibitor0.6507
P-glycoprotein inhibitor IINon-inhibitor0.8227
Renal organic cation transporterNon-inhibitor0.8698
CYP450 2C9 substrateNon-substrate0.8526
CYP450 2D6 substrateNon-substrate0.8946
CYP450 3A4 substrateSubstrate0.6553
CYP450 1A2 substrateNon-inhibitor0.5515
CYP450 2C9 inhibitorNon-inhibitor0.7963
CYP450 2D6 inhibitorNon-inhibitor0.8072
CYP450 2C19 inhibitorNon-inhibitor0.719
CYP450 3A4 inhibitorInhibitor0.5377
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7556
Ames testNon AMES toxic0.7104
CarcinogenicityNon-carcinogens0.9587
BiodegradationNot ready biodegradable0.6052
Rat acute toxicity2.7260 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9288
hERG inhibition (predictor II)Non-inhibitor0.6964
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Nebuliser solutionInhalation use10 μg/ml
Nebuliser solutionInhalation use20 μg/ml
Solutionrespiratory (inhalation).01 mg/mL
Solutionrespiratory (inhalation).02 mg/mL
Prices
Unit descriptionCostUnit
Ventavis 10 mcg/1 ml solution74.4USD ml
Ventavis 20 mcg/1 ml solution74.4USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityVery slightly solubleNot Available
logP4.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00874 mg/mLALOGPS
logP4.22ALOGPS
logP3.56ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)4.66ChemAxon
pKa (Strongest Basic)-0.87ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area77.76 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity105.18 m3·mol-1ChemAxon
Polarizability42.68 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesB01AC11
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (244 KB)
MSDSDownload (67.1 KB)
Interactions
Drug Interactions
Drug
AbciximabIloprost may increase the anticoagulant activities of Abciximab.
AcebutololIloprost may increase the hypotensive activities of Acebutolol.
AceclofenacThe therapeutic efficacy of Iloprost can be decreased when used in combination with Aceclofenac.
AcenocoumarolIloprost may increase the anticoagulant activities of Acenocoumarol.
AcenocoumarolThe risk or severity of adverse effects can be increased when Acenocoumarol is combined with Iloprost.
Acetylsalicylic acidThe therapeutic efficacy of Iloprost can be decreased when used in combination with Acetylsalicylic acid.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Iloprost is combined with Acetylsalicylic acid.
AdapaleneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Adapalene.
AliskirenIloprost may increase the hypotensive activities of Aliskiren.
AlprenololIloprost may increase the hypotensive activities of Alprenolol.
AlprostadilAlprostadil may increase the anticoagulant activities of Iloprost.
AlprostadilIloprost may increase the antiplatelet activities of Alprostadil.
AlteplaseIloprost may increase the anticoagulant activities of Alteplase.
AlteplaseThe risk or severity of adverse effects can be increased when Alteplase is combined with Iloprost.
ALX-0081Iloprost may increase the anticoagulant activities of ALX-0081.
ALX-0081The risk or severity of adverse effects can be increased when ALX-0081 is combined with Iloprost.
AmbrisentanIloprost may increase the hypotensive activities of Ambrisentan.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Iloprost.
AmlodipineIloprost may increase the hypotensive activities of Amlodipine.
AnagrelideAnagrelide may increase the anticoagulant activities of Iloprost.
AncrodIloprost may increase the anticoagulant activities of Ancrod.
AncrodThe risk or severity of adverse effects can be increased when Ancrod is combined with Iloprost.
AnistreplaseIloprost may increase the anticoagulant activities of Anistreplase.
AnistreplaseThe risk or severity of adverse effects can be increased when Anistreplase is combined with Iloprost.
AntipyrineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Antipyrine.
Antithrombin III humanIloprost may increase the anticoagulant activities of Antithrombin III human.
ApixabanIloprost may increase the anticoagulant activities of Apixaban.
ApixabanThe risk or severity of adverse effects can be increased when Apixaban is combined with Iloprost.
ApremilastThe therapeutic efficacy of Iloprost can be decreased when used in combination with Apremilast.
AprotininThe therapeutic efficacy of Iloprost can be decreased when used in combination with Aprotinin.
ArdeparinIloprost may increase the anticoagulant activities of Ardeparin.
ArdeparinThe risk or severity of adverse effects can be increased when Ardeparin is combined with Iloprost.
ArgatrobanIloprost may increase the anticoagulant activities of Argatroban.
AstaxanthinIloprost may increase the anticoagulant activities of Astaxanthin.
AstaxanthinThe risk or severity of adverse effects can be increased when Astaxanthin is combined with Iloprost.
AtenololIloprost may increase the hypotensive activities of Atenolol.
AzapropazoneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Azapropazone.
AzelastineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Azelastine.
AzelastineIloprost may increase the antiplatelet activities of Azelastine.
BalsalazideThe therapeutic efficacy of Iloprost can be decreased when used in combination with Balsalazide.
BatroxobinIloprost may increase the anticoagulant activities of Batroxobin.
BatroxobinThe risk or severity of adverse effects can be increased when Batroxobin is combined with Iloprost.
BecaplerminIloprost may increase the anticoagulant activities of Becaplermin.
BemiparinIloprost may increase the anticoagulant activities of Bemiparin.
BemiparinThe risk or severity of adverse effects can be increased when Bemiparin is combined with Iloprost.
BenazeprilIloprost may increase the hypotensive activities of Benazepril.
BendroflumethiazideIloprost may increase the hypotensive activities of Bendroflumethiazide.
BenoxaprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Benoxaprofen.
BepridilIloprost may increase the hypotensive activities of Bepridil.
BeraprostIloprost may increase the anticoagulant activities of Beraprost.
BetaxololIloprost may increase the hypotensive activities of Betaxolol.
BethanidineIloprost may increase the hypotensive activities of Bethanidine.
BimatoprostIloprost may increase the hypotensive activities of Bimatoprost.
BisoprololIloprost may increase the hypotensive activities of Bisoprolol.
BivalirudinIloprost may increase the anticoagulant activities of Bivalirudin.
BivalirudinThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Iloprost.
BosentanIloprost may increase the hypotensive activities of Bosentan.
BretyliumIloprost may increase the hypotensive activities of Bretylium.
BrimonidineIloprost may increase the hypotensive activities of Brimonidine.
BromfenacThe therapeutic efficacy of Iloprost can be decreased when used in combination with Bromfenac.
BupranololIloprost may increase the hypotensive activities of Bupranolol.
CandesartanIloprost may increase the hypotensive activities of Candesartan.
CandoxatrilIloprost may increase the hypotensive activities of Candoxatril.
CangrelorIloprost may increase the anticoagulant activities of Cangrelor.
CaptoprilIloprost may increase the hypotensive activities of Captopril.
CarprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Carprofen.
CarteololIloprost may increase the hypotensive activities of Carteolol.
CarvedilolIloprost may increase the hypotensive activities of Carvedilol.
CastanospermineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Castanospermine.
CelecoxibThe therapeutic efficacy of Iloprost can be decreased when used in combination with Celecoxib.
CeliprololIloprost may increase the hypotensive activities of Celiprolol.
CertoparinIloprost may increase the anticoagulant activities of Certoparin.
ChloroquineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Chloroquine.
ChlorothiazideIloprost may increase the hypotensive activities of Chlorothiazide.
ChlorthalidoneIloprost may increase the hypotensive activities of Chlorthalidone.
CilazaprilIloprost may increase the hypotensive activities of Cilazapril.
CilostazolIloprost may increase the anticoagulant activities of Cilostazol.
Citric AcidIloprost may increase the anticoagulant activities of Citric Acid.
ClonidineIloprost may increase the hypotensive activities of Clonidine.
ClonixinThe therapeutic efficacy of Iloprost can be decreased when used in combination with Clonixin.
ClopidogrelClopidogrel may increase the anticoagulant activities of Iloprost.
CollagenaseThe risk or severity of adverse effects can be increased when Iloprost is combined with Collagenase.
CryptenamineIloprost may increase the hypotensive activities of Cryptenamine.
CyclothiazideIloprost may increase the hypotensive activities of Cyclothiazide.
D-LimoneneThe therapeutic efficacy of Iloprost can be decreased when used in combination with D-Limonene.
Dabigatran etexilateIloprost may increase the anticoagulant activities of Dabigatran etexilate.
Dabigatran etexilateThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Iloprost.
DalteparinIloprost may increase the anticoagulant activities of Dalteparin.
DalteparinThe risk or severity of adverse effects can be increased when Dalteparin is combined with Iloprost.
DanaparoidIloprost may increase the anticoagulant activities of Danaparoid.
DanaparoidThe risk or severity of adverse effects can be increased when Danaparoid is combined with Iloprost.
DasatinibDasatinib may increase the anticoagulant activities of Iloprost.
DebrisoquinIloprost may increase the hypotensive activities of Debrisoquin.
DefibrotideIloprost may increase the anticoagulant activities of Defibrotide.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Iloprost is combined with Deoxycholic Acid.
DeserpidineIloprost may increase the hypotensive activities of Deserpidine.
DesirudinIloprost may increase the anticoagulant activities of Desirudin.
DesirudinThe risk or severity of adverse effects can be increased when Desirudin is combined with Iloprost.
DesmoteplaseIloprost may increase the anticoagulant activities of Desmoteplase.
DesmoteplaseThe risk or severity of adverse effects can be increased when Desmoteplase is combined with Iloprost.
DextranIloprost may increase the anticoagulant activities of Dextran.
Dextran 40Iloprost may increase the anticoagulant activities of Dextran 40.
Dextran 70Iloprost may increase the anticoagulant activities of Dextran 70.
Dextran 75Iloprost may increase the anticoagulant activities of Dextran 75.
DiazoxideIloprost may increase the hypotensive activities of Diazoxide.
DiclofenacThe therapeutic efficacy of Iloprost can be decreased when used in combination with Diclofenac.
DicoumarolIloprost may increase the anticoagulant activities of Dicoumarol.
DicoumarolThe risk or severity of adverse effects can be increased when Dicoumarol is combined with Iloprost.
DiflunisalThe therapeutic efficacy of Iloprost can be decreased when used in combination with Diflunisal.
DiflunisalThe risk or severity of adverse effects can be increased when Iloprost is combined with Diflunisal.
DiltiazemIloprost may increase the hypotensive activities of Diltiazem.
DipyridamoleDipyridamole may increase the anticoagulant activities of Iloprost.
DitazoleIloprost may increase the anticoagulant activities of Ditazole.
DitazoleThe risk or severity of adverse effects can be increased when Ditazole is combined with Iloprost.
DorzolamideIloprost may increase the hypotensive activities of Dorzolamide.
DoxazosinIloprost may increase the hypotensive activities of Doxazosin.
Drotrecogin alfaIloprost may increase the anticoagulant activities of Drotrecogin alfa.
Drotrecogin alfaThe risk or severity of adverse effects can be increased when Drotrecogin alfa is combined with Iloprost.
DroxicamThe therapeutic efficacy of Iloprost can be decreased when used in combination with Droxicam.
Edetic AcidIloprost may increase the anticoagulant activities of Edetic Acid.
EdoxabanIloprost may increase the anticoagulant activities of Edoxaban.
EfonidipineIloprost may increase the hypotensive activities of Efonidipine.
EnalaprilIloprost may increase the hypotensive activities of Enalapril.
EnalaprilatIloprost may increase the hypotensive activities of Enalaprilat.
EnoxaparinIloprost may increase the anticoagulant activities of Enoxaparin.
EnoxaparinThe risk or severity of adverse effects can be increased when Enoxaparin is combined with Iloprost.
EpinastineEpinastine may increase the anticoagulant activities of Iloprost.
EpinastineIloprost may increase the antiplatelet activities of Epinastine.
EpirizoleThe therapeutic efficacy of Iloprost can be decreased when used in combination with Epirizole.
EpoprostenolIloprost may increase the hypotensive activities of Epoprostenol.
EpoprostenolEpoprostenol may increase the anticoagulant activities of Iloprost.
EprosartanIloprost may increase the hypotensive activities of Eprosartan.
EptifibatideEptifibatide may increase the anticoagulant activities of Iloprost.
EtanerceptThe therapeutic efficacy of Iloprost can be decreased when used in combination with Etanercept.
Ethyl biscoumacetateIloprost may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl biscoumacetateThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Iloprost.
EtodolacThe therapeutic efficacy of Iloprost can be decreased when used in combination with Etodolac.
EtofenamateThe therapeutic efficacy of Iloprost can be decreased when used in combination with Etofenamate.
EtoricoxibThe therapeutic efficacy of Iloprost can be decreased when used in combination with Etoricoxib.
Evening primrose oilThe therapeutic efficacy of Iloprost can be decreased when used in combination with Evening primrose oil.
exisulindThe therapeutic efficacy of Iloprost can be decreased when used in combination with exisulind.
FelodipineIloprost may increase the hypotensive activities of Felodipine.
FenbufenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Fenbufen.
FenoldopamIloprost may increase the hypotensive activities of Fenoldopam.
FenoprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Fenoprofen.
FibrinolysinIloprost may increase the anticoagulant activities of Fibrinolysin.
FibrinolysinThe risk or severity of adverse effects can be increased when Fibrinolysin is combined with Iloprost.
FloctafenineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Floctafenine.
FlunixinThe therapeutic efficacy of Iloprost can be decreased when used in combination with Flunixin.
FlurbiprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Flurbiprofen.
Fondaparinux sodiumIloprost may increase the anticoagulant activities of Fondaparinux sodium.
FosinoprilIloprost may increase the hypotensive activities of Fosinopril.
GlucosamineGlucosamine may increase the antiplatelet activities of Iloprost.
GuanabenzIloprost may increase the hypotensive activities of Guanabenz.
GuanadrelIloprost may increase the hypotensive activities of Guanadrel.
GuanethidineIloprost may increase the hypotensive activities of Guanethidine.
GuanfacineIloprost may increase the hypotensive activities of Guanfacine.
HeparinIloprost may increase the anticoagulant activities of Heparin.
HeparinThe risk or severity of adverse effects can be increased when Heparin is combined with Iloprost.
HexamethoniumIloprost may increase the hypotensive activities of Hexamethonium.
HirulogIloprost may increase the anticoagulant activities of Hirulog.
HMPL-004The therapeutic efficacy of Iloprost can be decreased when used in combination with HMPL-004.
HydralazineIloprost may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideIloprost may increase the hypotensive activities of Hydrochlorothiazide.
HydroflumethiazideIloprost may increase the hypotensive activities of Hydroflumethiazide.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Iloprost is combined with Ibritumomab tiuxetan.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Iloprost.
IbudilastIbudilast may increase the anticoagulant activities of Iloprost.
IbudilastIloprost may increase the antiplatelet activities of Ibudilast.
IbuprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Ibuprofen.
IbuproxamThe therapeutic efficacy of Iloprost can be decreased when used in combination with Ibuproxam.
IcatibantThe therapeutic efficacy of Iloprost can be decreased when used in combination with Icatibant.
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Iloprost.
Icosapent ethylIloprost may increase the antiplatelet activities of Icosapent ethyl.
IfenprodilIfenprodil may increase the anticoagulant activities of Iloprost.
IfenprodilIloprost may increase the antiplatelet activities of Ifenprodil.
IndapamideIloprost may increase the hypotensive activities of Indapamide.
IndenololIloprost may increase the hypotensive activities of Indenolol.
IndomethacinThe therapeutic efficacy of Iloprost can be decreased when used in combination with Indomethacin.
IndoprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Indoprofen.
IndoraminIloprost may increase the hypotensive activities of Indoramin.
IrbesartanIloprost may increase the hypotensive activities of Irbesartan.
IsoxicamThe therapeutic efficacy of Iloprost can be decreased when used in combination with Isoxicam.
IsradipineIloprost may increase the hypotensive activities of Isradipine.
KebuzoneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Kebuzone.
KetoprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Ketoprofen.
KetorolacThe therapeutic efficacy of Iloprost can be decreased when used in combination with Ketorolac.
LabetalolIloprost may increase the hypotensive activities of Labetalol.
LacidipineIloprost may increase the hypotensive activities of Lacidipine.
LatanoprostIloprost may increase the hypotensive activities of Latanoprost.
LeflunomideThe therapeutic efficacy of Iloprost can be decreased when used in combination with Leflunomide.
LepirudinIloprost may increase the anticoagulant activities of Lepirudin.
LepirudinThe risk or severity of adverse effects can be increased when Lepirudin is combined with Iloprost.
LercanidipineIloprost may increase the hypotensive activities of Lercanidipine.
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Iloprost.
LisinoprilIloprost may increase the hypotensive activities of Lisinopril.
LofexidineIloprost may increase the hypotensive activities of Lofexidine.
LornoxicamThe therapeutic efficacy of Iloprost can be decreased when used in combination with Lornoxicam.
LosartanIloprost may increase the hypotensive activities of Losartan.
LoxoprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Loxoprofen.
LumiracoxibThe therapeutic efficacy of Iloprost can be decreased when used in combination with Lumiracoxib.
MacitentanIloprost may increase the hypotensive activities of Macitentan.
Magnesium salicylateThe therapeutic efficacy of Iloprost can be decreased when used in combination with Magnesium salicylate.
ManidipineIloprost may increase the hypotensive activities of Manidipine.
MasoprocolThe therapeutic efficacy of Iloprost can be decreased when used in combination with Masoprocol.
MecamylamineIloprost may increase the hypotensive activities of Mecamylamine.
Meclofenamic acidThe therapeutic efficacy of Iloprost can be decreased when used in combination with Meclofenamic acid.
Mefenamic acidThe therapeutic efficacy of Iloprost can be decreased when used in combination with Mefenamic acid.
MeloxicamThe therapeutic efficacy of Iloprost can be decreased when used in combination with Meloxicam.
MesalazineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Iloprost is combined with Mesalazine.
MetamizoleThe therapeutic efficacy of Iloprost can be decreased when used in combination with Metamizole.
MethyldopaIloprost may increase the hypotensive activities of Methyldopa.
MetipranololIloprost may increase the hypotensive activities of Metipranolol.
MetolazoneIloprost may increase the hypotensive activities of Metolazone.
MetoprololIloprost may increase the hypotensive activities of Metoprolol.
MibefradilIloprost may increase the hypotensive activities of Mibefradil.
MilrinoneMilrinone may increase the anticoagulant activities of Iloprost.
MilrinoneIloprost may increase the antiplatelet activities of Milrinone.
MinoxidilIloprost may increase the hypotensive activities of Minoxidil.
MoexiprilIloprost may increase the hypotensive activities of Moexipril.
MoxonidineIloprost may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe therapeutic efficacy of Iloprost can be decreased when used in combination with Mycophenolate mofetil.
Mycophenolic acidThe therapeutic efficacy of Iloprost can be decreased when used in combination with Mycophenolic acid.
NabumetoneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Nabumetone.
NadololIloprost may increase the hypotensive activities of Nadolol.
NadroparinIloprost may increase the anticoagulant activities of Nadroparin.
NadroparinThe risk or severity of adverse effects can be increased when Nadroparin is combined with Iloprost.
NaftifineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Naftifine.
NaproxenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Naproxen.
NCX 4016The therapeutic efficacy of Iloprost can be decreased when used in combination with NCX 4016.
NCX 4016Iloprost may increase the anticoagulant activities of NCX 4016.
NebivololIloprost may increase the hypotensive activities of Nebivolol.
NepafenacThe therapeutic efficacy of Iloprost can be decreased when used in combination with Nepafenac.
NicardipineIloprost may increase the hypotensive activities of Nicardipine.
NicorandilIloprost may increase the hypotensive activities of Nicorandil.
Niflumic AcidThe therapeutic efficacy of Iloprost can be decreased when used in combination with Niflumic Acid.
NiguldipineIloprost may increase the hypotensive activities of Niguldipine.
NilvadipineIloprost may increase the hypotensive activities of Nilvadipine.
NimesulideThe therapeutic efficacy of Iloprost can be decreased when used in combination with Nimesulide.
NimesulideIloprost may increase the antiplatelet activities of Nimesulide.
NimodipineIloprost may increase the hypotensive activities of Nimodipine.
NisoldipineIloprost may increase the hypotensive activities of Nisoldipine.
NitrendipineIloprost may increase the hypotensive activities of Nitrendipine.
NitroprussideIloprost may increase the hypotensive activities of Nitroprusside.
ObinutuzumabThe risk or severity of adverse effects can be increased when Iloprost is combined with Obinutuzumab.
OlmesartanIloprost may increase the hypotensive activities of Olmesartan.
OlopatadineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Olopatadine.
OlsalazineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Olsalazine.
OmapatrilatIloprost may increase the hypotensive activities of Omapatrilat.
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Iloprost.
OrgoteinThe therapeutic efficacy of Iloprost can be decreased when used in combination with Orgotein.
OtamixabanIloprost may increase the anticoagulant activities of Otamixaban.
OxaprozinThe therapeutic efficacy of Iloprost can be decreased when used in combination with Oxaprozin.
OxprenololIloprost may increase the hypotensive activities of Oxprenolol.
OxyphenbutazoneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Oxyphenbutazone.
ParecoxibThe therapeutic efficacy of Iloprost can be decreased when used in combination with Parecoxib.
PargylineIloprost may increase the hypotensive activities of Pargyline.
ParnaparinIloprost may increase the anticoagulant activities of Parnaparin.
ParnaparinThe risk or severity of adverse effects can be increased when Parnaparin is combined with Iloprost.
PenbutololIloprost may increase the hypotensive activities of Penbutolol.
PentoliniumIloprost may increase the hypotensive activities of Pentolinium.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Iloprost.
Pentosan PolysulfateIloprost may increase the anticoagulant activities of Pentosan Polysulfate.
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Iloprost.
PerindoprilIloprost may increase the hypotensive activities of Perindopril.
PhenindioneIloprost may increase the anticoagulant activities of Phenindione.
PhenindioneThe risk or severity of adverse effects can be increased when Phenindione is combined with Iloprost.
PhenoxybenzamineIloprost may increase the hypotensive activities of Phenoxybenzamine.
PhenprocoumonIloprost may increase the anticoagulant activities of Phenprocoumon.
PhenprocoumonThe risk or severity of adverse effects can be increased when Phenprocoumon is combined with Iloprost.
PhentolamineIloprost may increase the hypotensive activities of Phentolamine.
PhenylbutazoneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Phenylbutazone.
PimecrolimusThe therapeutic efficacy of Iloprost can be decreased when used in combination with Pimecrolimus.
PinacidilIloprost may increase the hypotensive activities of Pinacidil.
PindololIloprost may increase the hypotensive activities of Pindolol.
PirfenidoneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Pirfenidone.
PiroxicamThe therapeutic efficacy of Iloprost can be decreased when used in combination with Piroxicam.
PlasminIloprost may increase the anticoagulant activities of Plasmin.
PlasminThe risk or severity of adverse effects can be increased when Plasmin is combined with Iloprost.
PolythiazideIloprost may increase the hypotensive activities of Polythiazide.
PrasugrelIloprost may increase the anticoagulant activities of Prasugrel.
PrazosinIloprost may increase the hypotensive activities of Prazosin.
PropacetamolThe therapeutic efficacy of Iloprost can be decreased when used in combination with Propacetamol.
PropranololIloprost may increase the hypotensive activities of Propranolol.
Protein CIloprost may increase the anticoagulant activities of Protein C.
Protein CThe risk or severity of adverse effects can be increased when Protein C is combined with Iloprost.
ProtocatechualdehydeIloprost may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The therapeutic efficacy of Iloprost can be decreased when used in combination with PTC299.
QuinaprilIloprost may increase the hypotensive activities of Quinapril.
RamiprilIloprost may increase the hypotensive activities of Ramipril.
RemikirenIloprost may increase the hypotensive activities of Remikiren.
RescinnamineIloprost may increase the hypotensive activities of Rescinnamine.
ReserpineIloprost may increase the hypotensive activities of Reserpine.
ResveratrolThe therapeutic efficacy of Iloprost can be decreased when used in combination with Resveratrol.
ResveratrolIloprost may increase the antiplatelet activities of Resveratrol.
ReteplaseIloprost may increase the anticoagulant activities of Reteplase.
ReteplaseThe risk or severity of adverse effects can be increased when Reteplase is combined with Iloprost.
ReviparinIloprost may increase the anticoagulant activities of Reviparin.
ReviparinThe risk or severity of adverse effects can be increased when Reviparin is combined with Iloprost.
RidogrelRidogrel may increase the anticoagulant activities of Iloprost.
RidogrelIloprost may increase the antiplatelet activities of Ridogrel.
RiociguatIloprost may increase the hypotensive activities of Riociguat.
RivaroxabanIloprost may increase the anticoagulant activities of Rivaroxaban.
RivaroxabanThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Iloprost.
RofecoxibThe therapeutic efficacy of Iloprost can be decreased when used in combination with Rofecoxib.
RosiglitazoneIloprost may increase the anticoagulant activities of Rosiglitazone.
RosiglitazoneThe risk or severity of adverse effects can be increased when Rosiglitazone is combined with Iloprost.
SalicylamideThe therapeutic efficacy of Iloprost can be decreased when used in combination with Salicylamide.
Salicylic acidThe therapeutic efficacy of Iloprost can be decreased when used in combination with Salicylic acid.
Salicylic acidThe risk or severity of adverse effects can be increased when Iloprost is combined with Salicylic acid.
SalsalateThe therapeutic efficacy of Iloprost can be decreased when used in combination with Salsalate.
SaprisartanIloprost may increase the hypotensive activities of Saprisartan.
SCH-530348SCH-530348 may increase the anticoagulant activities of Iloprost.
SCH-530348Iloprost may increase the antiplatelet activities of SCH-530348.
SelexipagIloprost may increase the hypotensive activities of Selexipag.
SelexipagThe risk or severity of adverse effects can be increased when Selexipag is combined with Iloprost.
SeratrodastThe therapeutic efficacy of Iloprost can be decreased when used in combination with Seratrodast.
SevofluraneSevoflurane may increase the anticoagulant activities of Iloprost.
SevofluraneIloprost may increase the antiplatelet activities of Sevoflurane.
SitaxentanIloprost may increase the hypotensive activities of Sitaxentan.
SpiraprilIloprost may increase the hypotensive activities of Spirapril.
SRT501The therapeutic efficacy of Iloprost can be decreased when used in combination with SRT501.
SRT501Iloprost may increase the antiplatelet activities of SRT501.
StreptokinaseIloprost may increase the anticoagulant activities of Streptokinase.
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Iloprost.
SulfasalazineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Sulfasalazine.
SulindacThe therapeutic efficacy of Iloprost can be decreased when used in combination with Sulindac.
SulodexideIloprost may increase the anticoagulant activities of Sulodexide.
SulodexideThe risk or severity of adverse effects can be increased when Sulodexide is combined with Iloprost.
SuprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Suprofen.
TelmisartanIloprost may increase the hypotensive activities of Telmisartan.
TemocaprilIloprost may increase the hypotensive activities of Temocapril.
TenecteplaseIloprost may increase the anticoagulant activities of Tenecteplase.
TenecteplaseThe risk or severity of adverse effects can be increased when Tenecteplase is combined with Iloprost.
TenoxicamThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tenoxicam.
TepoxalinThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tepoxalin.
TeriflunomideThe therapeutic efficacy of Iloprost can be decreased when used in combination with Teriflunomide.
TerlipressinIloprost may increase the hypotensive activities of Terlipressin.
TesmilifeneTesmilifene may increase the anticoagulant activities of Iloprost.
TesmilifeneIloprost may increase the antiplatelet activities of Tesmilifene.
Tiaprofenic acidThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tiaprofenic acid.
TiboloneIloprost may increase the hypotensive activities of Tibolone.
TicagrelorIloprost may increase the anticoagulant activities of Ticagrelor.
TicagrelorThe risk or severity of adverse effects can be increased when Ticagrelor is combined with Iloprost.
TiclopidineTiclopidine may increase the anticoagulant activities of Iloprost.
TicrynafenIloprost may increase the hypotensive activities of Ticrynafen.
TimololIloprost may increase the hypotensive activities of Timolol.
TinzaparinIloprost may increase the anticoagulant activities of Tinzaparin.
TinzaparinThe risk or severity of adverse effects can be increased when Tinzaparin is combined with Iloprost.
TipranavirTipranavir may increase the antiplatelet activities of Iloprost.
TirofibanTirofiban may increase the anticoagulant activities of Iloprost.
TolazolineIloprost may increase the hypotensive activities of Tolazoline.
Tolfenamic AcidThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tolfenamic Acid.
TolmetinThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tolmetin.
TorasemideIloprost may increase the hypotensive activities of Torasemide.
TositumomabThe risk or severity of adverse effects can be increased when Iloprost is combined with Tositumomab.
TrandolaprilIloprost may increase the hypotensive activities of Trandolapril.
TranilastThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tranilast.
TranilastIloprost may increase the antiplatelet activities of Tranilast.
TrapidilTrapidil may increase the anticoagulant activities of Iloprost.
TrapidilIloprost may increase the antiplatelet activities of Trapidil.
TravoprostIloprost may increase the hypotensive activities of Travoprost.
TreprostinilIloprost may increase the hypotensive activities of Treprostinil.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Iloprost.
TrichlormethiazideIloprost may increase the hypotensive activities of Trichlormethiazide.
TriflusalIloprost may increase the anticoagulant activities of Triflusal.
TrimazosinIloprost may increase the hypotensive activities of Trimazosin.
TrimethaphanIloprost may increase the hypotensive activities of Trimethaphan.
Trisalicylate-cholineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Trisalicylate-choline.
UnoprostoneIloprost may increase the hypotensive activities of Unoprostone.
UrokinaseIloprost may increase the anticoagulant activities of Urokinase.
UrokinaseThe risk or severity of adverse effects can be increased when Urokinase is combined with Iloprost.
ValdecoxibThe therapeutic efficacy of Iloprost can be decreased when used in combination with Valdecoxib.
ValsartanIloprost may increase the hypotensive activities of Valsartan.
Vitamin EVitamin E may increase the antiplatelet activities of Iloprost.
VorapaxarIloprost may increase the anticoagulant activities of Vorapaxar.
WarfarinIloprost may increase the anticoagulant activities of Warfarin.
WarfarinThe risk or severity of adverse effects can be increased when Warfarin is combined with Iloprost.
XimelagatranIloprost may increase the anticoagulant activities of Ximelagatran.
XimelagatranThe risk or severity of adverse effects can be increased when Ximelagatran is combined with Iloprost.
XylometazolineIloprost may increase the hypotensive activities of Xylometazoline.
ZaltoprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Zaltoprofen.
ZileutonThe therapeutic efficacy of Iloprost can be decreased when used in combination with Zileuton.
ZomepiracThe therapeutic efficacy of Iloprost can be decreased when used in combination with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
Receptor for prostacyclin (prostaglandin I2 or PGI2). The activity of this receptor is mediated by G(s) proteins which activate adenylate cyclase.
Gene Name:
PTGIR
Uniprot ID:
P43119
Molecular Weight:
40955.485 Da
References
  1. Takamatsu H, Tsukada H, Watanabe Y, Cui Y, Kataoka Y, Hosoya T, Suzuki M, Watanabe Y: Specific ligand for a central type prostacyclin receptor attenuates neuronal damage in a rat model of focal cerebral ischemia. Brain Res. 2002 Jan 25;925(2):176-82. [PubMed:11792366 ]
  2. Crutchley DJ, Solomon DE, Conanan LB: Prostacyclin analogues inhibit tissue factor expression in the human monocytic cell line THP-1 via a cyclic AMP-dependent mechanism. Arterioscler Thromb. 1992 Jun;12(6):664-70. [PubMed:1375507 ]
  3. Schermuly RT, Pullamsetti SS, Breitenbach SC, Weissmann N, Ghofrani HA, Grimminger F, Nilius SM, Schror K, Kirchrath JM, Seeger W, Rose F: Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs. Respir Res. 2007 Jan 26;8:4. [PubMed:17257398 ]
  4. Idzko M, Hammad H, van Nimwegen M, Kool M, Vos N, Hoogsteden HC, Lambrecht BN: Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function. J Clin Invest. 2007 Feb;117(2):464-72. [PubMed:17273558 ]
  5. Tsai AL, Vijjeswarapu H, Wu KK: Interaction between platelet receptor and iloprost isomers. Biochim Biophys Acta. 1988 Jul 21;942(2):220-6. [PubMed:2456096 ]
  6. Olschewski H, Rose F, Schermuly R, Ghofrani HA, Enke B, Olschewski A, Seeger W: Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther. 2004 May;102(2):139-53. [PubMed:15163595 ]
  7. Anderson JR, Nawarskas JJ: Pharmacotherapeutic management of pulmonary arterial hypertension. Cardiol Rev. 2010 May-Jun;18(3):148-62. doi: 10.1097/CRD.0b013e3181d4e921. [PubMed:20395700 ]
  8. Mubarak KK: A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med. 2010 Jan;104(1):9-21. doi: 10.1016/j.rmed.2009.07.015. Epub 2009 Aug 15. [PubMed:19683911 ]
  9. Krug S, Sablotzki A, Hammerschmidt S, Wirtz H, Seyfarth HJ: Inhaled iloprost for the control of pulmonary hypertension. Vasc Health Risk Manag. 2009;5(1):465-74. [PubMed:19475782 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Prostaglandin e receptor activity
Specific Function:
Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(q) proteins which activate a phosphatidylinositol-calcium second messenger system. May play a role as an important modulator of renal function. Implicated the smooth muscle contractile response to PGE2 in various tissues.
Gene Name:
PTGER1
Uniprot ID:
P34995
Molecular Weight:
41800.655 Da
References
  1. Sharif NA, Davis TL: Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques. J Pharm Pharmacol. 2002 Apr;54(4):539-47. [PubMed:11999132 ]
  2. Walch L, de Montpreville V, Brink C, Norel X: Prostanoid EP(1)- and TP-receptors involved in the contraction of human pulmonary veins. Br J Pharmacol. 2001 Dec;134(8):1671-8. [PubMed:11739243 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Metal ion binding
Specific Function:
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
Gene Name:
PDE4A
Uniprot ID:
P27815
Molecular Weight:
98142.155 Da
References
  1. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, Bohm M, Sybrecht GW: Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001 Sep 11;104(11):1218-22. [PubMed:11551870 ]
  2. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Weissmann N, Schudt C, Tenor H, Seeger W, Grimminger F: Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit Care Med. 2002 Nov;30(11):2489-92. [PubMed:12441759 ]
  3. Schermuly RT, Leuchte H, Ghofrani HA, Weissmann N, Rose F, Kohstall M, Olschewski H, Schudt C, Grimminger F, Seeger W, Walmrath D: Zardaverine and aerosolised iloprost in a model of acute respiratory failure. Eur Respir J. 2003 Aug;22(2):342-7. [PubMed:12952271 ]
  4. Grant PG, Mannarino AF, Colman RW: cAMP-mediated phosphorylation of the low-Km cAMP phosphodiesterase markedly stimulates its catalytic activity. Proc Natl Acad Sci U S A. 1988 Dec;85(23):9071-5. [PubMed:2461561 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Metal ion binding
Specific Function:
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in mediating central nervous system effects of therapeutic agents ranging from antidepressants to antiasthmatic and anti-inflammatory agents.
Gene Name:
PDE4B
Uniprot ID:
Q07343
Molecular Weight:
83342.695 Da
References
  1. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, Bohm M, Sybrecht GW: Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001 Sep 11;104(11):1218-22. [PubMed:11551870 ]
  2. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Weissmann N, Schudt C, Tenor H, Seeger W, Grimminger F: Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit Care Med. 2002 Nov;30(11):2489-92. [PubMed:12441759 ]
  3. Schermuly RT, Leuchte H, Ghofrani HA, Weissmann N, Rose F, Kohstall M, Olschewski H, Schudt C, Grimminger F, Seeger W, Walmrath D: Zardaverine and aerosolised iloprost in a model of acute respiratory failure. Eur Respir J. 2003 Aug;22(2):342-7. [PubMed:12952271 ]
  4. Grant PG, Mannarino AF, Colman RW: cAMP-mediated phosphorylation of the low-Km cAMP phosphodiesterase markedly stimulates its catalytic activity. Proc Natl Acad Sci U S A. 1988 Dec;85(23):9071-5. [PubMed:2461561 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Metal ion binding
Specific Function:
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
Gene Name:
PDE4C
Uniprot ID:
Q08493
Molecular Weight:
79900.795 Da
References
  1. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, Bohm M, Sybrecht GW: Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001 Sep 11;104(11):1218-22. [PubMed:11551870 ]
  2. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Weissmann N, Schudt C, Tenor H, Seeger W, Grimminger F: Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit Care Med. 2002 Nov;30(11):2489-92. [PubMed:12441759 ]
  3. Schermuly RT, Leuchte H, Ghofrani HA, Weissmann N, Rose F, Kohstall M, Olschewski H, Schudt C, Grimminger F, Seeger W, Walmrath D: Zardaverine and aerosolised iloprost in a model of acute respiratory failure. Eur Respir J. 2003 Aug;22(2):342-7. [PubMed:12952271 ]
  4. Grant PG, Mannarino AF, Colman RW: cAMP-mediated phosphorylation of the low-Km cAMP phosphodiesterase markedly stimulates its catalytic activity. Proc Natl Acad Sci U S A. 1988 Dec;85(23):9071-5. [PubMed:2461561 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Ubiquitin protein ligase binding
Specific Function:
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
Gene Name:
PDE4D
Uniprot ID:
Q08499
Molecular Weight:
91114.1 Da
References
  1. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, Bohm M, Sybrecht GW: Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001 Sep 11;104(11):1218-22. [PubMed:11551870 ]
  2. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Weissmann N, Schudt C, Tenor H, Seeger W, Grimminger F: Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit Care Med. 2002 Nov;30(11):2489-92. [PubMed:12441759 ]
  3. Schermuly RT, Leuchte H, Ghofrani HA, Weissmann N, Rose F, Kohstall M, Olschewski H, Schudt C, Grimminger F, Seeger W, Walmrath D: Zardaverine and aerosolised iloprost in a model of acute respiratory failure. Eur Respir J. 2003 Aug;22(2):342-7. [PubMed:12952271 ]
  4. Grant PG, Mannarino AF, Colman RW: cAMP-mediated phosphorylation of the low-Km cAMP phosphodiesterase markedly stimulates its catalytic activity. Proc Natl Acad Sci U S A. 1988 Dec;85(23):9071-5. [PubMed:2461561 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Serine-type endopeptidase activity
Specific Function:
Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. Plays a direct role in facilitating neuronal migration.
Gene Name:
PLAT
Uniprot ID:
P00750
Molecular Weight:
62916.495 Da
References
  1. Kerins DM, Roy L, Kunitada S, Adedoyin A, FitzGerald GA, Fitzgerald DJ: Pharmacokinetics of tissue-type plasminogen activator during acute myocardial infarction in men. Effect of a prostacyclin analogue. Circulation. 1992 Feb;85(2):526-32. [PubMed:1370924 ]
  2. Nicolini FA, Mehta JL, Nichols WW, Saldeen TG, Grant M: Prostacyclin analogue iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis. Circulation. 1990 Mar;81(3):1115-22. [PubMed:1689620 ]
  3. Nichols WW, Nicolini FA, Saldeen TG, Mehta JL: Combined thrombolytic effects of tissue-plasminogen activator and a fibrinogen-degradation product peptide 6A or iloprost. J Cardiovasc Pharmacol. 1991 Aug;18(2):231-6. [PubMed:1717784 ]
  4. Nizankowski R, Krzanowski M, Musial J, Szczeklik A: [Effect of thromboxane A2 synthetase inhibitor and prostacyclin analogue on arterial blood pressure, fibrinolysis and platelet function in patients with hypertension]. Pol Tyg Lek. 1991 Jan 7-14;46(1-3):18-21. [PubMed:1726988 ]
  5. Herczenik E, Bouma B, Korporaal SJ, Strangi R, Zeng Q, Gros P, Van Eck M, Van Berkel TJ, Gebbink MF, Akkerman JW: Activation of human platelets by misfolded proteins. Arterioscler Thromb Vasc Biol. 2007 Jul;27(7):1657-65. Epub 2007 May 17. [PubMed:17510465 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name:
SLCO2B1
Uniprot ID:
O94956
Molecular Weight:
76709.98 Da
References
  1. Nishio T, Adachi H, Nakagomi R, Tokui T, Sato E, Tanemoto M, Fujiwara K, Okabe M, Onogawa T, Suzuki T, Nakai D, Shiiba K, Suzuki M, Ohtani H, Kondo Y, Unno M, Ito S, Iinuma K, Nunoki K, Matsuno S, Abe T: Molecular identification of a rat novel organic anion transporter moat1, which transports prostaglandin D(2), leukotriene C(4), and taurocholate. Biochem Biophys Res Commun. 2000 Sep 7;275(3):831-8. [PubMed:10973807 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
May mediate the release of newly synthesized prostaglandins from cells, the transepithelial transport of prostaglandins, and the clearance of prostaglandins from the circulation. Transports PGD2, as well as PGE1, PGE2 and PGF2A.
Gene Name:
SLCO2A1
Uniprot ID:
Q92959
Molecular Weight:
70043.33 Da
References
  1. Lu R, Kanai N, Bao Y, Schuster VL: Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J Clin Invest. 1996 Sep 1;98(5):1142-9. [PubMed:8787677 ]
  2. Kanai N, Lu R, Satriano JA, Bao Y, Wolkoff AW, Schuster VL: Identification and characterization of a prostaglandin transporter. Science. 1995 May 12;268(5212):866-9. [PubMed:7754369 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as estrone-3-sulfate (PubMed:10873595). Mediates transport of prostaglandins (PG) E1 and E2, thyroxine (T4), deltorphin II, BQ-123 and vasopressin, but not DPDPE (a derivative of enkephalin lacking an N-terminal tyrosine residue), estrone-3-sulfate, taurocholate, digoxin nor DHEAS (PubMed:16971491).
Gene Name:
SLCO3A1
Uniprot ID:
Q9UIG8
Molecular Weight:
76552.135 Da
References
  1. Adachi H, Suzuki T, Abe M, Asano N, Mizutamari H, Tanemoto M, Nishio T, Onogawa T, Toyohara T, Kasai S, Satoh F, Suzuki M, Tokui T, Unno M, Shimosegawa T, Matsuno S, Ito S, Abe T: Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1188-97. [PubMed:14631946 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23